Trevi Therapeutics IncNASDAQ:TRVI
- LAST PRICE2.8600
- TODAY'S CHANGE (%)0.0400 (1.4184%)
- Bid / Lots2.8500/ 7
- Ask / Lots2.8700/ 7
- Open / Previous Close2.8000 / 2.8200
- Day Range
- 52 Week Range
- Volume24,263
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TRVI |
|---|---|---|
| 09:32 ET | 3508 | 2.81 |
| 09:33 ET | 818 | 2.79 |
| 09:35 ET | 100 | 2.79 |
| 09:37 ET | 1086 | 2.77 |
| 09:39 ET | 1400 | 2.79 |
| 09:42 ET | 500 | 2.81 |
| 09:44 ET | 100 | 2.79 |
| 09:46 ET | 400 | 2.79 |
| 09:53 ET | 200 | 2.79 |
| 09:57 ET | 500 | 2.81 |
| 10:00 ET | 100 | 2.82 |
| 10:02 ET | 100 | 2.82 |
| 10:04 ET | 100 | 2.84 |
| 10:06 ET | 1800 | 2.82 |
| 10:08 ET | 400 | 2.82 |
| 10:09 ET | 2304 | 2.82 |
| 10:13 ET | 200 | 2.815 |
| 10:15 ET | 662 | 2.835 |
| 10:18 ET | 100 | 2.83 |
| 10:22 ET | 3135 | 2.85 |
| 10:24 ET | 706 | 2.855 |
| 10:26 ET | 100 | 2.855 |
| 10:27 ET | 500 | 2.86 |
Nov 8, 2024
DJ Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham, from 4:41AM ET on Friday Nov 08, 2024 by Dow Jones
4:41AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
DJ Trevi Therapeutics Is Maintained at Buy by EF Hutton, from 8:59AM ET on Thursday Nov 07, 2024 by Dow Jones
8:59AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 06, 2024 by Dow JonesPress Release: Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
Oct 30, 2024
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Trevi Therapeutics Inc | 216.8M | -6.5x | --- |
Zentalis Pharmaceuticals Inc | 216.9M | -1.2x | --- |
Benitec Biopharma Inc | 222.4M | -1.3x | --- |
Onkure Therapeutics Inc | 206.6M | -1.2x | --- |
Tevogen Bio Holdings Inc | 227.0M | 3.4x | --- |
Climb Bio Inc | 205.2M | -1.4x | --- |
Company Information
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Contact Information
- Headquarters
- 195 Church St Fl 14NEW HAVEN, CT, United States 06510-2009
- Phone
- 203-304-2499
- Fax
- 203-304-2434
Executives
- Non-Executive Chairman of the Board
- David Meeker
- President, Chief Executive Officer, Director
- Jennifer Good
- Co-Founder, Chief Science Officer
- Thomas Sciascia
- Chief Financial Officer
- Lisa Delfini
- Chief Development Officer
- James Cassella
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $216.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 76.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-0.44 |
Book Value | $1.21 |
P/E Ratio | -6.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
